SCIENTIFIC REPORTS

OPEN

The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM

Received: 29 October 2014

Accepted: 30 June 2015

Published: 26 August 2015

Virginie Follin-Arbelet¹, Kristine Misund², Elin Hallan Naderi¹, Hege Ugland¹, Anders Sundan² & Heidi Kiil Blomhoff¹

We have previously demonstrated that activation of the cyclic adenosine monophosphate (cAMP) pathway kills multiple myeloma (MM) cells both *in vitro* and *in vivo*. In the present study we have investigated the potential of enhancing the killing of MM cell lines and primary MM cells by combining the cAMP-elevating compound forskolin with the commonly used MM therapeutic drugs melphalan, cyclophosphamide, doxorubicin, bortezomib and dexamethasone. We observed that forskolin potentiated the killing induced by all the tested agents as compared to treatment with the single agents alone. In particular, forskolin had a synergistic effect on the dexamethasone-responsive cell lines H929 and OM-2. By knocking down the proapoptotic BCL-2 family member BIM, we proved this protein to be involved in the synergistic induction of apoptosis by dexamethasone and forskolin. The ability of forskolin to maintain the killing of MM cells even at lower concentrations of the conventional agents suggests that forskolin may be used to diminish treatment-associated side effects. Our findings support a potential role of forskolin in combination with current conventional agents in the treatment of MM.

Multiple myeloma (MM) is an incurable plasma cell malignancy that accounts for approximately 1% of neoplastic disorders worldwide¹. It is characterized by accumulation of malignant cells in the bone marrow leading to osteolytic bone lesions and impaired hematopoiesis. Clinical manifestations include anemia, recurrent infections, bone pain, fractures and hypercalcemia². Patients with MM have a median survival of 3 to 5 years³. The standard treatment of the disease is chemotherapy with or without autologous stem cell transplantation³. Although the emergence of new drugs has changed the landscape of MM treatment, patients experience drug-mediated side effects such as fatigue, anemia, and peripheral neuropathy^{4–6}. Furthermore, in almost all cases, patients relapse and are resistant to subsequent therapy⁷. Consequently, new therapeutic strategies are required to improve the outcome and the survival of MM patients.

Modulation of the cAMP signaling has previously shown promising results in MM^{8,9}. We demonstrated that elevation of intracellular cAMP levels induces apoptosis in both MM cell lines and patient tumor cells^{8,10}. Additionally, we observed that injection of the cAMP-elevating agent forskolin delays MM tumor growth in a mouse model. Importantly, interleukin 6 (IL-6), a central cytokine promoting MM cells growth and survival^{11,12}, did not prevent the cAMP-mediated apoptosis of the MM cells¹⁰. Taken together with the reported synergy between adenosine receptor agonists and phosphodiesterase

¹Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, PO Box 1112-Blindern, N-0317 Oslo, Norway. ²KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, N-7489 Trondheim, Norway. Correspondence and requests for materials should be addressed to H.K.B. (email: h.k.blomhoff@medisin.uio.no)

inhibitors to inhibit cell proliferation and induce death of MM cells¹³, our previous observations^{8,10} indicate that cAMP-elevating agents such as forskolin might have a therapeutic potential in MM.

Forskolin is a diterpene produced by the roots of the Indian plant *Coleus forskohlii*¹⁴. This plant has been used for centuries in Hindu Ayurvedic medicine¹⁵. Forskolin raises intracellular cAMP levels by directly activating adenylyl cyclase, an enzyme that generates cAMP from ATP. Although forskolin has been reported to modulate other cellular processes, such as ion channels^{16,17}, our previous studies have demonstrated that it induces MM cell death solely through elevation of cAMP levels^{8,10}. Forskolin or its derivative, colforsin daropate, has been tested in several clinical settings including cardiovascular diseases^{18,19}, obesity²⁰, psychiatric disorders²¹ and asthma²², and clinical studies with oral administration of forskolin 50 mg/day have not revealed significant side effects in patients^{20,23}. In the present study, we have investigated the effect of forskolin in MM cells in combination with clinically relevant MM therapeutic agents: DNA-damaging agents including the anthracycline antibiotic doxorubicin, the alkylating agent cyclophosphamide and melphalan, the proteasome inhibitor bortezomib, and the glucocorticoid dexamethasone. Cell death was evaluated in multiple myeloma cell lines as well as in primary MM cells from patients.

We here show that forskolin together with most of the agents tested has an additive effect on cell death. Furthermore, even suboptimal concentrations of forskolin alone gives as good, or even better, response as any of the single therapeutic drug. In particular, dexamethasone and forskolin had a synergistic effect on cell death in H929 and OPM-2 cells. We found that the cell death induced by the combination of dexamethasone and forskolin involved the induction of the pro-apoptotic protein BIM. Taken into account the adverse side effects of current MM therapeutic agents, we propose forskolin as an adjuvant in combination with dexamethasone to reduce the side effects and increase the efficiency of MM treatments.

Materials and Methods

Chemicals and Antibodies. Forskolin and dexamethasone (Sigma-Aldrich, St Louis, MO, USA) were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 30 mM and 10 mM respectively. Stock solutions were aliquoted and stored at -20°C . Melphalan (Sigma-Aldrich) was dissolved in acidified ethanol at a concentration of 50 mM, and aliquots were stored at -20°C . 4-hydro-peroxy-cyclophosphamide (Niomech, Bielefeld, Germany) and doxorubicin (Sigma-Aldrich) were dissolved in sterile distilled water at a concentration of 10 mM, and aliquots were stored at -80°C or 4°C respectively. Cyclophosphamide monohydrate (Sigma-Aldrich) was dissolved in sterile distilled water to 40 mg/ml. Bortezomib (Selleck Chemicals LLC, Houston, TX, USA) was dissolved in DMSO at a concentration of 10 mM, and aliquots were stored at -80°C . Propidium iodide (PI), DMSO, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich.

Antibodies against caspase 3, BIM, ERK1/2, phosphor-ERK1/2 (Thr202/Tyr204), and PARP were purchased from Cell Signaling Technologies (Danvers, MA, USA). Antibody against alpha tubulin (Novus Biologicals, Littleton, CO, USA) was used as loading control. Anti-rabbit and anti-mouse HRP-conjugated secondary antibodies were purchased from Bio-Rad (Hercules, CA, USA).

Cell Lines and Cell Culture. The human myeloma cell lines (HMCLs) U266, NCI-H929, RPMI 8226 and OPM-2 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). U266, RPMI 8226 and OPM-2 cells were cultured in RPMI 1640 (Lonza, Verviers, Belgium) containing 2 mM L-glutamine, supplemented with 15% (for U266 cells) or 10% (for OPM-2 and RPMI 8226 cells) heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich), 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin (Life Technologies, Grand Island, NY, USA). H929 cells were cultured in RPMI 1640 (Life Technologies) containing 2 mM L-glutamine, supplemented with 15% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich), 0.05 mM 2-mercaptoethanol (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin (Life Technologies). The human multiple myeloma INA-6 cell line was a kind gift from Dr. M. Gramatzki (Erlangen, Germany) and was cultured in RPMI 1640 (Life Technologies) containing 2 mM L-glutamine, supplemented with 1 ng/ml IL-6 (Life Technologies), 12 $\mu\text{g}/\text{ml}$ gentamycin (Sigma-Aldrich) and 10% heat-inactivated FBS (Lonza).

Primary Patients Samples. To obtain primary myeloma cells, CD138+ cells were isolated from bone marrow specimens obtained through the Norwegian Myeloma Biobank using RoboSep automated cell separator and Human CD138 Positive Selection Kit (StemCell Technologies). All subjects provided informed consent to participate in the study. This study was carried out in accordance with the approved guidelines by the Regional Ethics Committee.

Bone marrow stromal cells (BMSCs) were prepared as described previously²⁴. BMSC (2500 cells/well) were seeded in 96-well plates and allowed to adhere for at least 3 hours before addition of primary myeloma cells (5×10^3 cells/well). The cells were cultivated in RPMI medium supplemented with 2% human serum in a total volume of 200 μL /well, and drugs were added at the concentrations indicated. All samples were run in duplicate.

Small interference RNA transfections. Control siGenome Non-Targeting pool siRNA (D-001206-14) and BIM small interfering RNA (siRNA) (D-121190-01, D-121190-02, D-121190-03 and D-121190-04)

were obtained from Thermo Fisher Scientific Biosciences GmbH (St. Leon-Rot, Germany). OPM-2 cells were transfected with siRNA using Lipofectamine[®] RNAiMAX Transfection Reagent (Life technologies) according to manufacturer's protocol. Cells were rested 72 hours before being plated in experimental conditions. H929 cells were transfected with siRNA using Amaxa nucleofection technology (Lonza). Briefly, 2×10^6 cells were resuspended in Ingenio[™] Electroporation Solution (Mirus Bio LLC, Madison, WI, USA) and electroporated using program T-16. Cells were rested for 5 hours before being plated in experimental conditions. Knockdown was confirmed by western blot.

Specific cell death was calculated using the following equation: % specific cell death = (% experimental cell death in the drug-treated sample - % spontaneous cell death in the absence drug)/(100 - % spontaneous cell death in the absence of drug) x 100.

Analysis of Cell Death by Flow Cytometry. Flow cytometry analysis was performed on a FACSCalibur (BD Biosciences). For determination of cell viability by exclusion of PI, cells in culture were incubated with PI (20 µg/ml) prior to analysis. Percentage of dead cells was determined by gating for PI positive cells^{25,26}.

ScanR Viability Assay. This assay was performed as described previously²⁴. Briefly, after 3 days of incubation, YO-PRO-1 (1 µM) (Life Technologies) was added to the wells, and the plates incubated for 30 min at 37 °C. DRAQ5 (2.5 µM) (eBioscience, San Diego, CA, USA) was added to the wells 15 min before image acquisition without further processing. The ScanR microscope-based screening platform was used for automated image acquisition (Olympus). Images were analyzed using the Olympus ScanR Analysis software, where the cells were classified and gated by size, morphology and fluorescence intensity. Single, circular cells were classified and gated as myeloma cells. YO-PRO-1 is a DNA-binding dye that stains apoptotic cells. Myeloma cells that showed low YO-PRO-1 staining and high intensity DRAQ5 staining were characterized as viable.

Immunoblot Analysis. Cells were lysed in RIPA buffer (50 mM Tris [pH7.5], 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5 mM EDTA, 50 mM NaF, 10 mM β-glycerophosphate, 1 mM Na₃VO₄, 0.2 mM phenylmethylsulfonyl fluoride [PMSF], 10 µg/ml leupeptin, and 0.5% aprotinin) and equal amounts of proteins were separated by SDS-PAGE (Bio-Rad). After transfer to a nitrocellulose membrane (GE Healthcare, Amersham, UK) using a semi-dry transfer cell (Bio-Rad), proteins were detected by standard immunoblotting procedures. In brief, the nitrocellulose membranes were washed in Tris buffered saline and 0.1% Tween (TBST) and incubated in blocking solution (5% non-fat dry milk in TBST) at room temperature. After washing, the membranes were incubated overnight at 4 °C with primary antibodies diluted in 5% non-fat dry milk in TBST or 5% BSA in TBST. After washing in TBST, the membranes were incubated for 1 hour with HRP-conjugated secondary antibody diluted in blocking solution, followed by a final washing at room temperature. Immunoreactive proteins were visualized with the enhanced chemiluminescence detection system SuperSignal[®] West Dura Extended Duration substrate (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's protocol. Images were acquired with a Syngene ChemiGenius camera and presented by the GeneSnap software tool (Syngene, Cambridge, UK); the resulting SGD files were converted to JPEG files for image presentation. Densitometric analyses were performed on the primary SGD files to preserve maximal information, using the GeneTools 4.01 program (Syngene).

Statistical Analysis. The paired-samples t-test and the Wilcoxon matched-pairs signed rank test were applied to check the significance in cell lines experiments and primary patients' samples respectively using the Graph Pad Prism 6 software (San Diego, CA, USA). For cell lines experiments, histograms show mean values of the indicated number of experiments, with error bars corresponding to SEM values.

Determination of synergism by the combination index (CI) method. The interaction of forskolin and dexamethasone was determined by combination index (CI) method²⁷ using the CompuSyn software program (ComboSyn Inc., Paramus, NJ, USA) to determine whether the combination was antagonistic, additive or synergistic. Data from cell viability by exclusion of PI were expressed as the fractional inhibition by the individual drugs or the combination in drug-treated cells, and CI values between two drugs were generated. CI values greater than 1 indicate antagonism, CI value of 1 indicates an additive effect, and CI values of less than 1 indicate synergy.

Results

Forskolin in combination with therapeutic agents: effects on death of multiple myeloma cell lines. In order to determine the effects of forskolin and the different therapeutic agents on death of human myeloma cell lines (HMCLs), incorporation of PI was measured after 72 hours of treatment. As shown in Fig. 1, forskolin alone induced cell death in a dose-dependent manner in the five HMCLs tested, with U266, OPM-2 and INA-6 being more sensitive than H929 and RPMI 8226 cells. Hence, in the highly forskolin-sensitive cell line U266, forskolin more than doubled the extent of basal cell death at a concentration of 1 µM in U266 or 5 µM in H929, whereas the percentage of dead cells more than tripled when forskolin was used at a concentration of 5 µM in U266 and 50 µM in H929.

Figure 1. Dose dependent cell death induced by forskolin in five different HMCLs. U266, H929, INA-6, RPMI 8226 and OPM-2 cells were treated for 72 hours with low (panel a) and high (panel b) concentrations of forskolin (FSK). Cell death was assessed by propidium iodide exclusion (PI). The results are presented as mean of at least three independent experiments $\pm$ SEM.

We next evaluate the benefit of combining forskolin with different agents that are all frequently utilized in treatment of MM²⁸. First, we assessed the death of U266 and H929 cells treated with selected concentration of the DNA damaging agents melphalan, cyclophosphamide and doxorubicin as well as to the proteasome inhibitor bortezomib using ranges that are commonly applied in preclinical models^{29–32}. Both cell lines responded to the different drugs *per se* with variable sensitivity (Fig. 2a–d). Notably, only 2 μ M melphalan was required to obtain 70% cell death in H929 cells, whereas a ten times higher concentration of melphalan was needed to reach the same level of cell death in U266 (Fig. 2a). We next combined forskolin with these agents using a suboptimal concentration of forskolin together with a low dose of the particular agent. The level of cell death obtained by these treatments was compared to a single higher dose of that same agent. The rationale behind these experiments was to explore the possibility that the combined treatment with forskolin would make it possible to lower the concentrations of the therapeutic agents and still obtain a beneficial level of cell death. If so, this would potentially reduce the side effects of the conventional agents in a clinical setting. In U266 cells, 5 μ M of forskolin significantly increased the level of melphalan-induced cell death from approximately 30% (in the presence of 2 μ M melphalan alone) to 60% (when forskolin was combined with 2 μ M of melphalan) (Fig. 2e, left panel). Notably, the combination of melphalan (2 μ M) and forskolin (5 μ M) enhanced the cell death to the same extent as a single high dose (10 μ M) of melphalan alone. Forskolin also significantly improved the cell death induced by a single lower dose of melphalan in H929 cells (Fig. 2e, right panel), but in these cells a higher concentration (50 μ M) of forskolin was required. An even lower concentration of forskolin (1 μ M) was sufficient to enhance the death of U266 cells induced by 4 μ M of cyclophosphamide from 30% to 50% (Fig. 2f, left panel). Again the combined treatment with forskolin induced the same level of cell death as a five times higher concentration of cyclophosphamide alone. Comparable results were obtained upon treatment with doxorubicin (Fig. 2g). Hence, in both cell lines, forskolin significantly enhanced the cell death induced by 50 nM of doxorubicin (from 25% to 45%), and the combination with forskolin induced the same level of cell death as the three times higher concentration of doxorubicin alone (Fig. 2g). Forskolin also significantly improved bortezomib-induced cell death in both cell lines (Fig. 2h). It is noteworthy that in most of the cases we presently have analyzed, even a low concentration of forskolin alone was nearly as effective as the combination with a low concentration of the therapeutic agent. The exceptions, i.e. where there was a statistical significant higher cell death obtained by combining forskolin with a given agent as compared to forskolin alone, are indicated by asterisks in Fig. 2.

The combination of forskolin and dexamethasone synergistically enhanced the death of HMCLs. Unlike bortezomib and the different DNA damaging agents tested, the glucocorticoid

Figure 2. Effect of melphalan, 4-hydro-peroxy-cyclophosphamide, doxorubicin, and bortezomib alone or in combination with forskolin on cell death in U266 and H929 cells. U266 and H929 cells were treated with the indicated doses of melphalan (MEL) alone (panel a) or in combination with forskolin (FSK) (panel e), 4-hydro-peroxy-cyclophosphamide (CP) alone (panel b) or in combination with FSK (panel f), doxorubicin (DOXO) alone (panel c) or in combination with FSK (panel g), bortezomib (BTZ) alone (panel d) or in combination with FSK (panel h). Cell death was assessed by PI exclusion after 72 hours of treatment. The histograms represent the mean of at least three independent experiments $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$.

dexamethasone alone had no or modest effect in U266 and H929 respectively (Fig. 3a). The OPM-2 and the RPMI8226 MM cell line, however, were sensitive to dexamethasone treatment (Fig. 3a). Remarkably, dexamethasone was the only agent that was found to induce strong synergy at a low concentration of forskolin. Hence, in H929 cells, 1 μ M of forskolin and 0.1 μ M of dexamethasone alone did not induce any cell death, whereas the combination between these two compounds strongly enhanced the cell death from approximately 20% to 70% (Fig. 3b). The same combination also enhanced cell death in OPM-2 cells as compared to single agents alone (Fig. 3b). More moderate effect was obtained in RPMI8226 and INA-6 cell lines. Dexamethasone had no effect alone or in combination with forskolin in U266 cells (Fig. 3b). The combinatorial effect of forskolin with dexamethasone was evaluated by the CI method, and synergy was observed across a wide range of concentrations for the four MM cell lines tested (Fig. 3c). However, it is noteworthy that not all cell lines responded to the same extent. Hence, synergistic killing was stronger in H929 and OPM-2 cells as compared to the killing of RPMI8226 and INA-6 cells.

In order to establish that apoptosis was the mode of cell death induced by forskolin in combination with dexamethasone, apoptosis in terms of caspase activation was assessed in H929 and OPM-2 cells. Hence, caspase activation was determined by western blot analysis of cleaved caspase 3 and the caspase substrate poly (ADP-Ribose) polymerase (PARP). In accordance with the results on PI-incorporation, the western blot analysis showed that forskolin synergized with dexamethasone also in terms of caspase activation (Fig. 3d). Hence, the combination of 1 μ M of forskolin and 0.1 μ M of dexamethasone strongly enhanced the cleavage of both caspase 3 and PARP, whereas each of the compounds alone had negligible effects.

Figure 3. Combination of low doses of forskolin and dexamethasone induces synergistic cell death in HMCLs. (Panels **a** and **b**): U266, H929, OPM-2, RPMI8226 and INA-6 cells were treated for 72h with the indicated doses of dexamethasone (DEXA) (panel **a**) or with the indicated concentrations of forskolin (FSK) alone or in combination with DEXA (panel **b**). Cell death was assessed by propidium iodide exclusion (PI). The histograms represent the mean of at least three independent experiments $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$ relative to untreated cells. (Panel **c**): H929, OPM-2, RPMI8226 and INA-6 cells were treated with the indicated concentrations of FSK or DEXA alone or in combination for 72h. Cell death was assessed by propidium iodide exclusion (PI). Histograms represent average of at least three independent experiments $\pm$ SEM. *combination is synergistic (CI > 1). Panel **d**: H929 and OPM-2 were treated with the indicated doses of DEXA and FSK. After 24h, cells were subjected to western blot analysis for full length and cleaved products of caspase 3 and PARP. Tubulin was used as a loading control. One of three representative experiments is shown. The full size blots can be found in the Supplementary Figure S1.

Figure 4. Combination of low doses of forskolin and dexamethasone enhances the expression of BIM. H929 cells were incubated with the indicated concentrations of forskolin (FSK) and dexamethasone (DEXA). After 4 hours, cells were collected and subjected to western blot analysis of BIM and tubulin. The full size blots can be found in the Supplementary Figure S2. The histograms show the levels of BIM_{EL} relative to the level in untreated cells set as 1. The results are presented as mean $\pm$ SEM of four independent experiments. * $p < 0.05$.

Knock down of BIM partially prevents apoptosis induced by the combination of dexamethasone and forskolin. BCL-2 family members are essential players of the apoptotic machinery. Previous studies have established a role of the BH3-only Bcl-2 family member BIM in the cAMP-promoted apoptosis^{33,34}. In addition, BIM has been suggested to play an important role in glucocorticoid-mediated apoptosis³⁵. There are three splice variants of BIM protein (BIM_{EL}, BIM_L and BIM_S) and all of them are pro-apoptotic. We therefore assessed the expression of all 3 isoforms of BIM after dexamethasone and forskolin treatment in H929 cells. Interestingly, treatment of H929 cells with combined low doses of forskolin and dexamethasone triggered a four time increase in BIM_{EL} expression levels compared to control (Fig. 4), and the combination was significantly more potent to increase BIM_{EL} levels than dexamethasone or forskolin alone. BIM_L and BIM_S were also strongly enhanced by forskolin plus dexamethasone treatment. In contrast, examination of the other BCL-2 family members BCL-2, BCL-XL, and BAX revealed only minor alterations in protein expression (data not shown). ERK1/2 has been shown to promote BIM degradation³⁶. Consistently, we observed that forskolin alone or in combination with dexamethasone inhibited the activating phosphorylation of ERK (Fig. 4), suggesting that BIM upregulation could result from inhibition of ERK signaling.

To determine whether BIM mediated the apoptosis induced by the combination of forskolin and dexamethasone, BIM expression was knocked down by using the siRNA strategy. Quantification of protein bands by densitometry revealed that knock down reduced the levels of BIM_{EL} by 40% in OPM-2 cells and 30% in H929 cells as compared with control siRNA, and the levels of BIM_L and BIM_S were similarly knocked down (data not shown). Importantly, the knock down of BIM inhibited the apoptotic cell death induced by the combination of forskolin and dexamethasone in both H929 and OPM-2 MM cells. Hence, the induced activation of caspases, as envisioned by proteolytic cleavage of PARP and caspase 3, was markedly inhibited upon knock down of BIM both in H929 cells (Fig. 5a) and to a greater extent in OPM-2 (Fig. 5b). Furthermore, the cell death induced by the combination of forskolin and dexamethasone was significantly reduced by knocking down BIM in H929 cells as compared with cells treated with control siRNA (Fig. 5c). Knocking down BIM also decreased the cell death induced by combining forskolin and dexamethasone in OPM-2 cells, but the effect was less pronounced (data not shown). Taken together, these results suggest that apoptosis induced by the combination of forskolin and dexamethasone is at least in part mediated via BIM.

Figure 5. Knock down of BIM partially prevents apoptosis induced by the combination of dexamethasone and forskolin. H929 and OPM-2 cells were transfected with control siRNA or BIM siRNA using the Amaxa nucleofection technology and Lipofectamine transfection reagent, respectively. Forskolin (FSK, at a final concentration of 1 μ M) alone or in combination with dexamethasone (DEXA, at a final concentration of 0.1 μ M) was added to the cells 5 hours (for H929 cells) or 72 hours (for OPM-2 cells) after transfection. After 4 hours of treatment, the H929 cells (panel a) and OPM-2 cells (panel b) were collected and subjected to western blot analysis of BIM and tubulin, whereas the levels of full length and cleaved products of caspase 3 and PARP were assessed after 24 h of treatment. The full size blots can be found in the Supplementary Figure S3. (Panel c): After 48 hours of treatment, cell death was assessed by PI exclusion in U266. Histograms represent the percentage of drug-specific cell death of 3 independent experiments. * $p < 0.05$.

Forskolin enhances cell death mediated by therapeutic agents on primary cells from multiple myeloma patients. To support the notion that forskolin can be of potential use in MM therapy, CD138+ B cells isolated from ten patients with MM were co-cultured with bone marrow stromal cells and treated with forskolin in combination with melphalan, cyclophosphamide, bortezomib or dexamethasone, respectively. The cell death of primary myeloma cells was assessed after 72 h hours of treatment by using an automated fluorescence microscope platform as previously described²⁴. In accordance with the results obtained on cell lines (Figs 2 and 3), forskolin increased the activity of melphalan (Fig. 6a), bortezomib (Fig. 6c) and dexamethasone (Fig. 6d). The effect was statistically significant with low concentrations of bortezomib and melphalan, and with the two concentrations of dexamethasone that were tested. Forskolin also increased the activity of cyclophosphamide, however without reaching statistical

Figure 6. Effect of forskolin in combination with conventional therapeutic agents on primary MM cells. CD138+ B cells isolated from ten multiple myeloma patients (MMP) were co-cultured with bone marrow stromal cells (BMSCs) for 72h with or without the indicated dose of forskolin in combination with the indicated concentrations of melphalan (panel a), cyclophosphamide monohydrate (panel b), bortezomib (panel c) or dexamethasone (panel d). Cells were stained with DRAQ5/YO-PRO-1, and cell viability was evaluated by using the ScanR microscope as previously described²⁴. * $P < 0.05$, ** $P < 0.01$. Panel e: results from panel d presented as bar lines for each patients.

significance (Fig. 6b). It is noteworthy that the combination of forskolin and dexamethasone was the most efficient treatment combination in terms of killing the primary MM cells. Hence, 5 μ M of forskolin in combination with 1 μ M of dexamethasone reduced the viability of the MM cells to a larger extent than even a ten times higher concentration of dexamethasone alone (Fig. 6d). It should be noted that not all patient-derived MM cells responded to the combination of forskolin and dexamethasone. Hence, forskolin had no effect on dexamethasone-mediated killing of the three patient-derived cells MMP5, MMP6 and MMP10, and only minor potentiation of dexamethasone-induced killing was observed in MMP7 and MMP8 (Fig. 6e). Importantly however, forskolin potentiated the effect of dexamethasone in 5 of the 10 patient-derived MM cells, and in these cells the combination of dexamethasone and forskolin was always more effective than even a ten times higher dose of dexamethasone alone (Fig. 6e).

As it is well established that BMSC may confer treatment resistance to MM cells²⁴, it should be emphasized that forskolin alone or in combination with the conventional anticancer drugs in the present study was able to kill the primary MM cells even in the presence of BMSCs.

Discussion

Despite the development of new combination therapies during the past 15 years, the majority of multiple myeloma patients relapse, their tumor cells become chemoresistant, and they die from the disease. Furthermore, chemotherapeutic agents used for the treatment of MM have substantial side effects including peripheral neuropathy, thromboembolism, neutropenia, anemia, fatigue and gastrointestinal complications⁶. Hence, there is a need for new treatment strategies aiming at reducing side effects and enhancing the efficiency of existing MM therapies.

We previously showed that single treatment by forskolin kills MM cells *in vitro* and delays tumor growth *in vivo*⁸. Combined with the notion that clinical studies have reported limited side effects of forskolin^{20,23}, we wished to elucidate the potential of using forskolin in combination with existing therapies for MM. In the present study, we report that combination of forskolin with the common MM therapeutic agents melphalan, cyclophosphamide, doxorubicin, bortezomib, and dexamethasone significantly increased apoptosis compared to single agent treatment. In two different MM cell lines, combination of forskolin with low doses of DNA damaging agents induced the same extent of cell death as two to five times higher doses of the single agent treatment alone. Interestingly, dexamethasone and forskolin had a strong synergistic effect on cell death in H929 and OPM-2 cells. This is in line with a previous report demonstrating synergistic inhibition of MM cells between dexamethasone and PDE inhibitors and/or activators of the G protein coupled receptor adenosine A2A both of which can enhance cAMP levels in the cells^{13,37}. It should be noted that the combination of forskolin and dexamethasone was not equally potent in all MM cell lines. Hence, despite the fact that the Chou-Talalay method revealed synergistic killing also of RPMI8226 and INA-6 cells, these cells were much less responsive to the combination of forskolin and dexamethasone than were H929 and OPM2-cells.

Forskolin also enhanced melphalan- and dexamethasone-induced cell death in patient-derived primary MM cells. As it is well established that BMSCs may confer treatment resistance to MM cells^{24,38,39}, the ability of forskolin to kill primary myelomas was particularly interesting given the fact that the cells were co-cultured with BMSCs. Importantly, forskolin did not significantly decrease the viability of the BMSCs (data not shown) supporting the perception of low toxicity of forskolin on normal cells. It should be remarked that for four out of the ten MM patients primary cells we tested, forskolin alone had little or no effect on cell death, supporting the notion that forskolin should always be combined with conventional chemotherapy in clinical settings.

In an attempt to elucidate the mechanisms whereby forskolin may interfere with the various MM therapeutic agents, we investigated steps in the apoptotic pathway as well as upstream signaling events. The ability of forskolin alone or in combination with dexamethasone to kill MM cells was confirmed by assessing the cleavage of caspase 3 and PARP. Upstream activation of the intrinsic apoptotic pathway is regulated by BCL-2 family members. In this study, we demonstrated that forskolin plus dexamethasone treatment rapidly increases the levels of the pro-apoptotic BCL-2 member BIM. Notably, knocking down BIM partially prevented the cell death as well the caspase activation induced by the combination of forskolin and dexamethasone, suggesting the involvement of BIM in the apoptotic cell death. The present findings are in accordance with previous studies showing that BIM mRNA and protein expression is increased in response to activation of the cAMP/PKA pathway in certain T lymphoid cell lines^{40,41}, and that knock down of BIM with shRNA blunts cAMP-promoted apoptosis in the S49 murine T-lymphoma cell line⁴¹. Microarray analyses have also demonstrated that glucocorticoids can upregulate BIM levels in lymphoid cells^{35,42}. Hence, BIM has been suggested to be a convergence point for the killing of lymphoid cells by glucocorticoids and treatments that raise the levels of cAMP⁴⁰. Here we show for the first time that forskolin, a natural compound that raises intracellular levels of cAMP, is able to enhance the expression of BIM also in MM cells, and that forskolin synergizes with dexamethasone to induce BIM upregulation and apoptosis in MM cells.

How forskolin upregulates BIM remains unclear. The pro-apoptotic activity of BIM is regulated by transcriptional as well as posttranscriptional mechanisms. The forkhead-like transcription factor FOXO3a is a key transcriptional regulator of BIM⁴³, whereas posttranscriptional regulation of BIM occurs through a series of phosphorylation events. ERK phosphorylates FOXO3a thereby increasing its degradation via an MDM2-dependent proteasomal pathway⁴⁴. In addition, ERK has been shown to

regulate phosphorylation of BIM_{EL} on serine 69, hence promoting its degradation via the proteasomal pathway³⁶. In agreement with these results we found that ERK phosphorylation is inhibited by forskolin, thus providing a possible mechanism whereby forskolin may upregulate BIM.

Interactions between MM cells and the bone marrow microenvironment (BMM) activate a multitude of proliferative and anti-apoptotic signaling pathways, including the Ras–Raf–MAPK kinase (MEK)–extracellular signal-regulated kinase (ERK) pathway and the Janus kinase/signal transducer and activator of transcription (JAK–STAT) pathway⁴⁵. We have previously reported that forskolin kills U266 cells by inhibiting the JAK–STAT pathway¹⁰, and here we could show that forskolin alone or in combination with dexamethasone, melphalan or bortezomib (Fig. 4 and data not shown) also inhibit ERK-phosphorylation. Combined disruption of ERK-signaling and the JAK–STAT pathway is required to induce apoptosis of MM cells in the presence of BMSCs⁴⁶. Hence, by demonstrating the inhibition of both signaling pathways, the results of the present study support the clinical potential of combining forskolin with conventional therapeutic agents.

Natural compounds such as forskolin are often considered to be affordable and, although not necessarily true, to have low general toxicity⁴⁷. As many natural compounds have the advantage of targeting multiple signaling pathways^{48–51}, a growing number of clinical studies are now evaluating their potentials in cancer treatment in combination with conventional chemotherapies⁵². The present study opens for clinical studies along the same lines. The natural compound forskolin has for centuries been applied in traditional medicine¹⁵, and its safety has also been documented in conventional modern medicine²³. We suggest that forskolin, by targeting multiple signaling pathways in MM cells, might reduce the doses of chemotherapeutic agents required to kill such cells *in vivo* and thereby limit the severe side effects associated with current conventional therapies of MM.

References

- Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. *CA Cancer J. Clin.* **55**, 74–108 (2005).
- Laubach, J., Richardson, P. & Anderson, K. Multiple myeloma. *Annu. Rev. Med.* **62**, 249–264 (2011).
- Rajkumar, S. V. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. *Am. J. Hematol.* **88**, 226–235 (2013).
- Palumbo, A., Mateos, M. V., Bringhen, S. & San Miguel, J. F. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? *Blood Rev.* **25**, 181–191 (2011).
- Mateos, M. V. Management of treatment-related adverse events in patients with multiple myeloma. *Cancer Treat. Rev.* **36 Suppl 2**, S24–S32 (2010).
- Gay, F. & Palumbo, A. Management of disease- and treatment-related complications in patients with multiple myeloma. *Med. Oncol.* **27 Suppl 1**, S43–S52 (2010).
- Mahindra, A. *et al.* Latest advances and current challenges in the treatment of multiple myeloma. *Nat. Rev. Clin. Oncol.* **9**, 135–143 (2012).
- Follin-Arbelet, V. *et al.* Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. *BMC. Cancer* **11**, 301 (2011).
- Krett, N. L. *et al.* Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. *Clin. Cancer Res.* **3**, 1781–1787 (1997).
- Follin-Arbelet, V. *et al.* Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway. *Cancer Lett.* **335**, 323–331 (2013).
- Klein, B. *et al.* Interleukin-6 is the central tumor growth factor *in vitro* and *in vivo* in multiple myeloma. *Eur. Cytokine Netw.* **1**, 193–201 (1990).
- Klein, B., Zhang, X. G., Lu, Z. Y. & Bataille, R. Interleukin-6 in human multiple myeloma. *Blood* **85**, 863–872 (1995).
- Rickles, R. J. *et al.* Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies. *Blood* **116**, 593–602 (2010).
- Seamon, K. B., Padgett, W. & Daly, J. W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. *Proc. Natl. Acad. Sci. USA* **78**, 3363–3367 (1981).
- Valdés, L. J., Mislankar, S. G. & Paul, A. G. *Coleus barbatius* (C. forskohlii) (Lamiaceae) and the Potential New Drug Forskolin (Coleonol). *Economic Botany* **41**, 474–483 (1987).
- Laurenza, A., Sutkowski, E. M. & Seamon, K. B. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? *Trends Pharmacol. Sci.* **10**, 442–447 (1989).
- Ono, K., Fozzard, H. A. & Hanck, D. A. A direct effect of forskolin on sodium channel bursting. *Pflugers Arch.* **429**, 561–569 (1995).
- Kikura, M., Morita, K. & Sato, S. Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting. *Pharmacol. Res.* **49**, 275–281 (2004).
- Baumann, G., Felix, S., Sattelberger, U. & Klein, G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy—a comparative study with dobutamine and sodium nitroprusside. *J. Cardiovasc. Pharmacol.* **16**, 93–100 (1990).
- Godard, M. P., Johnson, B. A. & Richmond, S. R. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. *Obes. Res.* **13**, 1335–1343 (2005).
- Bersudsky, Y., Kotler, M., Shifrin, M. & Belmaker, R. H. A preliminary study of possible psychoactive effects of intravenous forskolin in depressed and schizophrenic patients. Short communication. *J. Neural Transm.* **103**, 1463–1467 (1996).
- Huerta, M., Urzua, Z., Trujillo, X., Gonzalez-Sanchez, R. & Trujillo-Hernandez, B. Forskolin compared with beclomethasone for prevention of asthma attacks: a single-blind clinical trial. *J. Int. Med. Res.* **38**, 661–668 (2010).
- Henderson, S. *et al.* Effects of *coleus forskohlii* supplementation on body composition and hematological profiles in mildly overweight women. *J. Int. Soc. Sports Nutr.* **2**, 54–62 (2005).
- Misund, K. *et al.* A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-cultured with Bone Marrow Stromal Cells. *J. Biomol. Screen.* **18**, 637–646 (2013).
- Darzynkiewicz, Z. *et al.* Features of apoptotic cells measured by flow cytometry. *Cytometry* **13**, 795–808 (1992).
- Kroemer, G. *et al.* Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. *Cell Death. Differ.* **16**, 3–11 (2009).

27. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* **58**, 621–681 (2006).
28. Gentile, M., Recchia, A. G., Mazzone, C. & Morabito, F. Emerging biological insights and novel treatment strategies in multiple myeloma. *Expert. Opin. Emerg. Drugs* **17**, 407–438 (2012).
29. Hideshima, T. *et al.* The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. *Cancer Res.* **61**, 3071–3076 (2001).
30. Kaufmann, M. *et al.* In-vitro testing of cyclophosphamide on tumors. *Naturwissenschaften* **62**, 446–447 (1975).
31. Haskell, C. M. & Sullivan, A. Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. *Cancer Res.* **34**, 2991–2994 (1974).
32. Rowley, M., Liu, P. & Van, N. B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. *Blood* **96**, 3175–3180 (2000).
33. Insel, P. A., Wilderman, A., Zhang, L., Keshwani, M. M. & Zambon, A. C. Cyclic AMP/PKA-Promoted Apoptosis: Insights from Studies of S49 Lymphoma Cells. *Horm. Metab. Res.* (2014).
34. Moujalled, D. *et al.* Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim. *EMBO Rep.* **12**, 77–83 (2011).
35. Wang, Z., Malone, M. H., He, H., McColl, K. S. & Distelhorst, C. W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. *J. Biol. Chem.* **278**, 23861–23867 (2003).
36. Luciano, F. *et al.* Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. *Oncogene* **22**, 6785–6793 (2003).
37. Rickles, R. J. *et al.* Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. *Mol. Cancer Ther.* **11**, 1432–1442 (2012).
38. Meads, M. B., Hazlehurst, L. A. & Dalton, W. S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. *Clin. Cancer Res.* **14**, 2519–2526 (2008).
39. Hao, M. *et al.* Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. *Leuk. Lymphoma* **52**, 1787–1794 (2011).
40. Zhang, L. & Insel, P. A. The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells. *J. Biol. Chem.* **279**, 20858–20865 (2004).
41. Zambon, A. C., Wilderman, A., Ho, A. & Insel, P. A. Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells. *J. Biol. Chem.* **286**, 33260–33267 (2011).
42. Erlacher, M. *et al.* BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells *in vivo*. *Blood* **106**, 4131–4138 (2005).
43. Dijkers, P. F., Medema, R. H., Lammers, J. W., Koenderman, L. & Coffey, P. J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. *Curr. Biol.* **10**, 1201–1204 (2000).
44. Yang, J. Y. *et al.* ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. *Nat. Cell Biol.* **10**, 138–148 (2008).
45. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. & Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nat. Rev. Cancer* **7**, 585–598 (2007).
46. Chatterjee, M. *et al.* Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. *Blood* **104**, 3712–3721 (2004).
47. Chinembiri, T. N., du Plessis, L. H., Gerber, M., Hamman, J. H. & du, P. J. Review of Natural Compounds for Potential Skin Cancer Treatment. *Molecules* **19**, 11679–11721 (2014).
48. Banerjee, S., Li, Y., Wang, Z. & Sarkar, F. H. Multi-targeted therapy of cancer by genistein. *Cancer Lett.* **269**, 226–242 (2008).
49. Kannappan, R., Gupta, S. C., Kim, J. H. & Aggarwal, B. B. Tocotrienols fight cancer by targeting multiple cell signaling pathways. *Genes Nutr.* **7**, 43–52 (2012).
50. Kunnumakkara, A. B., Anand, P. & Aggarwal, B. B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. *Cancer Lett.* **269**, 199–225 (2008).
51. Khan, N. & Mukhtar, H. Multitargeted therapy of cancer by green tea polyphenols. *Cancer Lett.* **269**, 269–280 (2008).
52. Uzoigwe, J. & Sauter, E. R. Cancer prevention and treatment using combination therapy with plant- and animal-derived compounds. *Expert. Rev. Clin. Pharmacol.* **5**, 701–709 (2012).

Acknowledgments

The work was supported by grants from the Norwegian Cancer Society, the Jahre Foundation, the Blix Family Foundation, the Research Council of Norway, K.G. Jebsen Foundation for Medical Research and the University of Oslo. The authors are grateful to Camilla Solberg and Jannicke Holmseth for excellent technical help.

Author Contributions

V.F.A. designed the research, performed experiments, analyzed data and wrote the paper; K.M. designed the research, performed experiments, and wrote the paper; H.U. performed experiments and helped in writing the paper, E.H.N. helped designing the research, analyzing the data and writing the paper. A.S. helped designing the research, provided material and helped in writing of the paper; H.K.B. designed the research, analyzed data, and wrote the paper. All authors have read and approved the manuscript. V.F.A., K.M. and H.U. performed experiments; V.F.A., K.M., E.H.N., A.S. and H.K.B. designed the research; A.S. provided primary sample material; V.F.A., E.H.N. and H.K.B. analyzed data; V.F.A., K.M. and H.K.B. wrote the paper. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Follin-Arbelet, V. *et al.* The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. *Sci. Rep.* **5**, 13001; doi: 10.1038/srep13001 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>